EUCTR2008-002693-35-GB进行中（未招募）1 期
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture
Eli Lilly and Company Ltd0 个研究点目标入组 171 人开始时间: 2008年10月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 171
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Men and postmenopausal women aged 50 to 78 years inclusive at the time of entry into the trial. In women, last menstrual period or bilateral oophorectomy has to occur at least 2 years prior to entry into the trial. Subjects must be able to walk unassisted prior to the fracture, and free of severe or chronically disabling conditions, including dementia and gait problems. Have a life expectancy of at least 3 years. AP lumbar spine (L-1 through L-4) BMD and/or femoral neck BMD and/or total hip BMD measurement of the contra lateral hip at least 2.0 SDs below the average bone mass for young women and men. Patient has sustained a unilateral, fracture of the trochanteric region caused by a low-energy injury. Fracture is treated with an intramedular hip nail or a sliding compression hip screw with or without a trochanteric stabilizing plate. Able to satisfactorily use a pen-type injection delivery system in the opinion of the investigator and willing to be trained on use of the pen-injector and willing to use the pen-injector on a daily basis, or is willing to receive daily subcutaneous injections from a care partner who has been trained to use the pen injector.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Clinically significant abnormal laboratory values (as defined by the investigator) of total alkaline phosphatase and/or abnormally elevated serum total calcium levels at the screening visit. Abnormally elevated values of serum intact PTH(1 84) at the screening visit. Severe vitamin D deficiency defined at 25-hydroxy-vitamin D levels. Abnormally elevated values of fT4 at the screening visit. Patients with sub-clinical hyperthyroidism, defined as abnormally low serum values of TSH with normal fT4 values, are eligible to participate in the study. History of unresolved skeletal diseases that affect bone metabolism including renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected), and intestinal malabsorption. Increased baseline risk of osteosarcoma; this includes patients with Paget’s disease of the bone, previous primary skeletal malignancy, or skeletal exposure to therapeutic irradiation. As elevation of serum skeletal alkaline phosphatase activity may indicate the presence of Paget’s disease, an unexplained elevation of this enzyme activity will also be exclusionary. History of a malignant neoplasm in the 5 years prior to Visit 1, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to entry into the study may enter the study. History of symptomatic nephro- or urolithiasis in the year prior to Visit 1. Active liver disease or clinical jaundice. Significantly impaired renal function. History of bone marrow or solid organ transplantation. Bilateral hip fractures. Previous fracture(s) or bone surgery in the currently fractured hip. Soft tissue infection at the operation site. Patient treated with hip prosthetic replacement techniques. Patient treated with external fixation of the petrochantic fracture or with ordinary Ender nails or 2D bent nails. Patient treated with bone grafting or osteotomies. Treatment with augmentation using any type of degradable cement, hydroxyapatite-coated implants or with non-invasive interventiones with ultrasound, magnetic field/electrical stimulation. Treatment with fluoride, stontium ranelate, IV/oral bisphosphonates, SERM, calcitonin, estrogen antagonists, tibolone. Prior treatment with PTH, teriparatide or risedronate or excipients of teriparatide or to any other form of PTH or PTH analogue. Presence of any condition which contraindicates risedronate therapy.
研究者
相似试验
进行中（未招募）
不适用
Comparison of the Effects of Teriparatide with those of Risendronate on Lumbar Spine Volumetric Bone Mineral Density in GLucocorticpid-Induced Osteoporosis in Men - GHDHEUCTR2006-006315-68-DEEli Lilly and Company Limited104
进行中（未招募）
不适用
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Volumetric Bone Mineral Density in Glucocorticoid-Induced Osteoporosis in Men - NDEUCTR2006-006315-68-ITEli Lilly and Company104
进行中（未招募）
1 期
Comparison of Teriparatide with Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip FracturePostmenopausal Women and Men with Low Bone Mass and a Recent Pertrochanteric FractureMedDRA version: 17.1Level: LLTClassification code 10031288Term: Osteoporosis with fractureSystem Organ Class: 100000004859EUCTR2008-002693-35-SEEli Lilly and Company Ltd285
进行中（未招募）
1 期
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture - GHDKPostmenopausal Women and Men with Low Bone Mass and a Recent Pertrochanteric FractureMedDRA version: 9.1Level: LLTClassification code 10031282Term: OsteoporosisEUCTR2008-002693-35-NOEli Lilly and Company Ltd171
进行中（未招募）
不适用
Comparison of the Effects of Teriparatide with those of Risendronate on Lumbar Spine Volumetric Bone Mineral Density in GLucocorticpid-Induced Osteoporosis in Men - GHDHMales with glucocorticoid-induced osteoporosisEUCTR2006-006315-68-GREli Lilly and Company Limited104